NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[ 1] SINGAPORE, May 30, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised...

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

SHENZHEN, China, May 29, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed...

SHEIN's Science-Based Net-Zero Target is Approved by SBTi

SHEIN's Science-Based Net-Zero Target is Approved by SBTi

SINGAPORE, May 27, 2025 /PRNewswire/ -- As a global online fashion and lifestyle retailer, we have reached a milestone in our climate journey with the Science Based Targets initiative (SBTi) validating our net-zero science-based target by 2050 and...

RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China

RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China

YANTAI, China, May 27, 2025 /PRNewswire/ -- On May 27, RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment...

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial

SUZHOU, China, May 26, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived subtype-specific neural regenerative cell therapy...

Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm

Yunji Selects WWC, P.C. as its Independent Registered Public Accounting Firm

HANGZHOU, China, May 22, 2025 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that the Company's board of directors and the audit committee of the board...

Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths

Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths

YUFLYMA ® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira ® (adalimumab) biosimilar [1] Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled...

JinkoSolar's EAGLE® Preserve Program Approved as the State of Washington's 1st Module Stewardship Program

JinkoSolar's EAGLE® Preserve Program Approved as the State of Washington's 1st Module Stewardship Program

CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. (the "Company," or "JinkoSolar") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that EAGLE® Preserve, its...

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

HONG KONG, May 16, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets...

Infineon gains approval of Science Based Targets initiative for ambitious CO2 emission reduction targets

Infineon gains approval of Science Based Targets initiative for ambitious CO2 emission reduction targets

Scope 1 and 2 targets meet highest SBTi standard for near-term reduction goals Infineon sets ambitious scope 3 target to further reduce emissions along the supply chain Active work with over one hundred suppliers to further reduce emissions MUNICH,...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • menu
    menu